| Not Yet Recruiting | ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 NCT07472322 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Recruiting | TIL Therapy in cSCC and MCC NCT07288073 | Karam Khaddour, MD, MS | Phase 2 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496 | University of Arizona | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of NCT06753136 | Istituto Oncologico Veneto IRCCS | N/A |
| Terminated | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) NCT06939036 | Ariceum Therapeutics GmbH | Phase 1 / Phase 2 |
| Not Yet Recruiting | Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns NCT06039033 | Power Life Sciences Inc. | — |
| Not Yet Recruiting | Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radioth NCT06448611 | University Hospital, Montpellier | — |
| Active Not Recruiting | Exercise to Boost Response to Checkpoint Blockade Immunotherapy NCT06008977 | AdventHealth Translational Research Institute | N/A |
| Recruiting | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma NCT06151236 | Melanoma Institute Australia | Phase 2 |
| Recruiting | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymph NCT06223659 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma NCT06056895 | University of Washington | Phase 2 |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel NCT06086288 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Recruiting | A Study of CRD3874-SI in People With Solid Tumors NCT06021626 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Me NCT05583708 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | L19IL2/L19TNF in Skin Cancer Patients NCT05329792 | Philogen S.p.A. | Phase 2 |
| Recruiting | Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma NCT05496036 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Active Not Recruiting | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery NCT05594290 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Active Not Recruiting | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors NCT05120271 | Sotio Biotech Inc. | Phase 1 / Phase 2 |
| Unknown | Immunological Variables Associated to ICI Toxicity in Cancer Patients NCT05429866 | Jules Bordet Institute | Phase 2 |
| Active Not Recruiting | Exercise to Boost Response to Checkpoint Blockade Immunotherapy NCT05358938 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Completed | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomaviru NCT05422781 | Immunomic Therapeutics, Inc. | Phase 1 |
| Recruiting | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 | Memgen, Inc. | Phase 1 |
| Recruiting | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in NCT05078047 | UNICANCER | Phase 3 |
| Recruiting | Hypofractionated Radiation Therapy for Merkel Cell Carcinoma NCT05100095 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With NCT04916002 | Regeneron Pharmaceuticals | Phase 2 |
| Withdrawn | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (M NCT04874831 | 4SC AG | Phase 2 |
| Active Not Recruiting | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Adv NCT04975152 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European NCT04705389 | University Hospital, Tours | N/A |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Personalised Immunotherapy Platform NCT06536257 | Melanoma Institute Australia | — |
| Active Not Recruiting | Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma NCT04869137 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Ce NCT04590781 | Xencor, Inc. | Phase 1 / Phase 2 |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034 | Incyte Corporation | Phase 1 |
| Active Not Recruiting | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma NCT04792073 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid NCT04725331 | Transgene | Phase 1 / Phase 2 |
| Terminated | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy NCT04596033 | Genocea Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma NCT04291885 | Melanoma and Skin Cancer Trials Limited | Phase 2 |
| Completed | Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti- NCT04393753 | 4SC AG | Phase 2 |
| Terminated | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic NCT04260802 | Ocellaris Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid NCT04242199 | Incyte Corporation | Phase 1 |
| Recruiting | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin NCT04349436 | Replimune, Inc. | Phase 1 / Phase 2 |
| Completed | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers NCT04160065 | TuHURA Biosciences, Inc. | Phase 1 |
| Terminated | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed Af NCT03853317 | ImmunityBio, Inc. | Phase 2 |
| Terminated | LITT and Pembrolizumab in Recurrent Brain Metastasis NCT04187872 | University of Florida | Phase 1 |
| Terminated | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 NCT03901573 | NeoImmuneTech | Phase 1 / Phase 2 |
| Recruiting | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers NCT03935893 | Udai Kammula | Phase 2 |
| Terminated | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors NCT04116320 | Craig L Slingluff, Jr | Phase 1 |
| Completed | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors NCT04157985 | Dan Zandberg | Phase 3 |
| Active Not Recruiting | A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma NCT04047251 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 1 |
| Terminated | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma NCT03988647 | Stanford University | Phase 2 |
| Terminated | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumor NCT04234113 | SOTIO Biotech AG | Phase 1 |
| Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular I NCT04106167 | Fate Therapeutics | — |
| Unknown | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carc NCT03787602 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) NCT03783078 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumo NCT03841110 | Fate Therapeutics | Phase 1 |
| Completed | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer NCT03798639 | Claire Verschraegen | Phase 1 |
| Active Not Recruiting | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Im NCT03228667 | ImmunityBio, Inc. | Phase 2 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Completed | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Ma NCT03629756 | Arcus Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | DOTATOC PET/CT for Imaging NET Patients NCT03583528 | British Columbia Cancer Agency | — |
| Completed | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies NCT03538028 | Incyte Biosciences International Sàrl | Phase 1 |
| Completed | T-VEC in Non-melanoma Skin Cancer NCT03458117 | University of Zurich | Phase 1 |
| Terminated | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metast NCT03435640 | Nektar Therapeutics | Phase 1 / Phase 2 |
| Withdrawn | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have NCT03167164 | ImmunityBio, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine NCT02831179 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes NCT03370861 | Washington University School of Medicine | — |
| Active Not Recruiting | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor NCT02978625 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers NCT03212404 | Checkpoint Therapeutics, Inc. | Phase 1 |
| Completed | Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study NCT03545334 | Insel Gruppe AG, University Hospital Bern | N/A |
| Active Not Recruiting | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma NCT03071406 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers NCT02643303 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Terminated | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis NCT02890368 | Pfizer | Phase 1 |
| Completed | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, NCT02819843 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC NCT05253144 | University of Birmingham | N/A |
| Unknown | French National Database of Rare Dermatological Cancers NCT03210935 | University Hospital, Lille | — |
| Completed | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma NCT02514824 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus NCT02479698 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Ob NCT02196961 | Prof. Dr. med. Dirk Schadendorf | Phase 2 |
| Terminated | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma NCT02036476 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma NCT02035657 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Terminated | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma NCT02054884 | Philogen S.p.A. | Phase 2 |
| Withdrawn | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma NCT01913691 | National Cancer Institute (NCI) | Phase 2 |
| Completed | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cance NCT01440816 | OncoSec Medical Incorporated | Phase 2 |
| Completed | Merkel Positron Emission Tomography (PET) Protocol NCT01013779 | Trans Tasman Radiation Oncology Group | Phase 2 |
| Completed | Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer NCT01526486 | Emory University | N/A |
| Completed | The Impact of Total Body Skin Examination on Skin Cancer Detection NCT00765193 | Medical University of Graz | N/A |
| Completed | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors NCT00346385 | ImmunoGen, Inc. | Phase 1 |
| Completed | Optical Biopsy of Human Skin in Conjunction With Laser Treatment NCT00540566 | University of California, Irvine | — |
| Available | IFx-Hu2.0 Expanded Access Program NCT04853602 | TuHURA Biosciences, Inc. | — |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respon NCT00003514 | Burzynski Research Institute | Phase 2 |